个性化文献订阅>期刊> Journal of Medicinal Chemistry
 

3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models

  作者 SOTH MICHAEL; HERMANN JOHANNES C; YEE CALVIN; ALAM MUZAFFAR; BARNETT JIM W; BERRY PAMELA; BROWNER MICHELLE F; FRANK KARL; FRAUCHIGER SANDRA; HARRIS SETH; HE YANG; HEKMATNEJAD MOHAMMAD; HENDRICKS THAN; HENNINGSEN ROBERT; HILGENKAMP RAMONA; HO HOANGDUNG; HOFFMAN ANN; HSU PEIYUAN; HU DONGQING; ITANO ANDREA; JAIMEFIGUEROA SAUL; JAHANGIR ALAM; JIN SUE; KUGLSTATTER ANDREAS; KUTACH ALAN K; LIAO CHENG; LYNCH STEPHEN; MENKE JOHN; NIU LINGHAO; PATEL VAISHALI; RAILKAR ARUNA; ROY DOUGLAS; SHAO ADA; SHAW DAVID; STEINER SANDRA; SUN YONGLIANG; TAN SENGLAI; WANG SANDRA; MINH DIEM VU  
  选自 期刊  Journal of Medicinal Chemistry;  卷期  2013年56-1;  页码  345-356  
  关联知识点  
 

[摘要]The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内